Overview

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and antiviral activity of etravirine in treatment-experienced human immunodeficiency virus (HIV) infected children and adolescents.

Phase:

Phase 2

Details

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Treatments:

Antiviral Agents
Etravirine